With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Takeda, coming off a high of 2024 growth, is pushing through what it says will be the worst of its Vyvanse-related declines.

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

Teva’s chief drug Austedo—approved in Huntington’s disease and tardive dyskinesia—grew sales 19% to $498 million for the ...

Vinay Prasad, M.D., has left the FDA, less than three months into the role as director of the Center for Biologics Evaluation ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Daré Bioscience has started a consumer awareness campaign to lay the foundations for the launch of its female sexual arousal drug, rolling out video and interactive content on a women’s health app.

At long last, the Trump administration’s much-ballyhooed tariffs on pharmaceutical imports are materializing in a trade deal ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

After a first half that saw Publicis Groupe snap up six companies around the world, the advertising giant is continuing its ...

The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has s | In a phase 3 trial, the newest Bruton’s tyrosine kinase inhibitor on the market, Eli Lilly’s Jaypirca, has shown its chops in a ...